Loading…
Gurugram-headquartered multi-specialty hospital chain (Medanta) offering tertiary/quaternary care across several Indian cities.
Gurugram-headquartered multi-specialty hospital chain (Medanta) offering tertiary/quaternary care across several Indian cities.
Charges patients for procedures, rooms and tests, with insurers, government schemes and self-paying patients all in the mix; profit rests on filling beds and operating theatres with complex cases. It grew around cardiac surgeon Naresh Trehan, with the Gurugram hospital as the flagship and newer hospitals in other cities still ramping up.
In one line: India's Cleveland Clinic-style super-specialty hospital operator.
Moat: narrow (brand, installed base). Reputation built on renowned physicians and large tertiary-care infrastructure.
Headquarters: Gurugram, India · Founded: 2004 · Employees: 14,777
Size Global Health (MEDANTA.NS) is an India Health Care company (Hospital/Nursing Management) with a market value of $3.95B, the 243rd largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,388 on 6 Nov 2026.
Performance Over six months the shares gained 15.0%, against 0.0% for the median peer and 0.0% for the India market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 26.2% over the last twelve months (peer median +12.9%); the operating margin is 16.8% (peer median 11.1%).
Valuation It trades at 51.1× forward earnings against a peer median of 41.6× (7th most expensive of 19).
Capital Return on invested capital runs 3.6 points above its cost of capital (11.1% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹50.5B | ₹43.3B | ₹36.5B | ₹32.5B | ₹26.9B |
| Revenue growth | — | +19% | +12% | +21% | — |
| Gross profit | ₹24.5B | ₹18.4B | ₹16.0B | ₹14.5B | ₹11.5B |
| EBITDA | ₹11.2B | ₹8.71B | ₹8.56B | ₹8.28B | ₹6.42B |
| Net income | ₹6.18B | ₹5.56B | ₹4.81B | ₹4.78B | ₹3.26B |
| Free cash flow | n/a | -₹2.25B | ₹177M | ₹3.61B | ₹3.81B |
| Capital expenditure | n/a | ₹9.79B | ₹6.48B | ₹2.79B | ₹2.36B |
| Total debt | ₹13.5B | ₹11.9B | ₹7.18B | ₹8.02B | ₹11.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Global Health MEDANTA.NS | $3.95B | +15% | +26% | 17% | 51.1× | n/a |
| Apollo Hospitals Enterprise APOLLOHOSP.NS | $12.8B | +8% | +19% | 12% | 49.3× | 32.2% |
| Max Healthcare Institute MAXHEALTH.NS | $9.61B | -8% | +15% | 21% | 49.7× | 43.2% |
| Fortis Healthcare FORTIS.NS | $6.13B | -19% | +18% | 17% | 45.0× | 41.0% |
| Narayana Hrudayalaya NH.NS | $4.11B | +3% | +71% | 13% | 36.5× | 31.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MEDANTA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.2% | +3.7% | 6th highest of 21 |
| 6-month return | +15.0% | 0.0% | 6th highest of 20 |
| Distance from 52-week high | -10.1% | -17.9% | 7th highest of 21 |
| Revenue growth (TTM) | +26.2% | +12.9% | 4th highest of 21 |
| Operating margin | 16.8% | 11.1% | 5th highest of 21 |
| Forward P/E | 51.1× | 41.6× | 7th most expensive of 19 |
| ROIC minus cost of capital | +3.6 pp | -2.6 pp | 5th highest of 21 |
| EV / EBITDA | 33.3× | 20.5× | 4th most expensive of 15 |
| Net debt / EBITDA | -0.0× | 3.8× | least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Global Health MEDANTA.NS | India | $3.95B | +15% | +26% | 17% | 51.1× | n/a | n/a |
| Narayana Hrudayalaya NH.NS | India | $4.11B | +3% | +71% | 13% | 36.5× | 31.1% | +25.0% |
| National HealthCare NHC | United States | $3.27B | +11% | +7% | -8% | n/a | 7.9% | +9.7% |
| Krishna Institute of Medical Sciences KIMS.NS | India | $3.21B | +2% | +31% | 12% | 70.0× | n/a | n/a |
| Surgery Partners SGRY | United States | $2.99B | +61% | +4% | 14% | 62.5× | 13.8% | +12.2% |
| Fortis Healthcare FORTIS.NS | India | $6.13B | -19% | +18% | 17% | 45.0× | 41.0% | +17.9% |
| Topchoice Medical 600763.SS | China | $2.51B | -11% | +7% | 26% | 26.7× | 13.6% | +6.9% |
| Ardent Health ARDT | United States | $2.44B | +71% | +3% | 4% | 14.5× | 4.0% | +8.7% |
| Aster DM Quality Care ASTERDM.NS | India | $6.57B | -3% | +16% | 14% | 49.6× | 55.3% | -11.6% |
| Chemed CHE | United States | $6.87B | +24% | +5% | 14% | 19.5× | 2.4% | +4.0% |
| Brookdale Senior Living BKD | United States | $2.15B | -31% | -4% | 5% | 127.7× | 22.4% | -1.4% |
| PACS PACS | United States | $7.87B | +48% | +11% | 8% | 19.2× | 7.6% | +29.7% |
| Huaxia Eye Hospital 301267.SZ | China | $1.92B | -16% | +2% | 15% | 24.7× | 3.8% | +10.4% |
| Extendicare EXE.TO | Canada | $1.87B | -9% | +31% | 9% | 19.4× | 11.2% | +8.5% |
| Ramsay Health Care RHC.AX | Australia | $8.87B | +52% | +4% | 5% | 32.4× | 14.3% | +8.3% |
| Manipal Health Enterprises MANIPALHOS.NS | India | $9.01B | n/a | +25% | 19% | 63.1× | 29.7% | +28.8% |
| Sienna Senior Living SIA.TO | Canada | $1.63B | -11% | +16% | 10% | 38.1× | 19.6% | +8.6% |
| Max Healthcare Institute MAXHEALTH.NS | India | $9.61B | -8% | +15% | 21% | 49.7× | 43.2% | +27.2% |
| Xi'an International Medical Investment 000516.SZ | China | $1.54B | 0% | -1% | -2% | n/a | 13.6% | +20.6% |
| Aevis Victoria AEVS.SW | Switzerland | $1.49B | +9% | +15% | -6% | 107.9× | 26.6% | +10.2% |
| Sanbo Hospital Management 301293.SZ | China | $1.48B | -21% | +17% | 6% | 148.9× | n/a | n/a |